Infectious disease

medical specialties

The week's innovation in infectious disease, published every Sunday for the week before: new technology, AI tools, devices, FDA decisions on new technology and new ways of delivering care, every item linked to its sources.

Reports say PAHO revoked U.S. measles elimination status; elebsiran-tobevibart meets hepatitis delta goal; doxycycline tied to pregnancy loss

A petri dish of pale agar dotted with round colonies of a few sizes, its clear lid tilted against it.

The Pan American Health Organization (PAHO) has revoked U.S. measles elimination status, according to a Wall Street Journal report cited by Reuters on Nov. 13, as confirmed U.S. cases reached 5,412 for 2026.

Vir Biotechnology said its hepatitis delta combination met the primary end point in a phase 3 trial, and a cohort study tied early-pregnancy doxycycline to higher pregnancy loss.

  • Public health Nov 13, 2026
    The Pan American Health Organization (PAHO) has revoked the measles elimination status of the United States, according to a Wall Street Journal report cited by Reuters on Nov. 13, Contagion Live reported; PAHO did not immediately respond to a request for comment on the report. Reuters had reported Nov. 11 that the determination was expected to be made public early the following week. The Centers for Disease Control and Prevention (CDC) reported 5,412 confirmed cases in 2026 as of Nov. 12; its website lists six deaths, while state health departments have reported 10, according to Contagion Live.
  • Research Nov 8, 2026
    Vir Biotechnology said 44% of patients given monthly subcutaneous elebsiran and tobevibart achieved undetectable hepatitis delta virus RNA with alanine aminotransferase normalization at week 48, the primary end point, versus 0% in the delayed-treatment group at week 12 (P < .0001), in the 124-patient phase 3 trial randomized 2:1. Undetectable virus at week 48, a key secondary end point, was reached by 79%. The topline results were presented in a late-breaking oral session at The Liver Meeting 2026, HCPLive reported Nov. 8, and Vir said it plans a U.S. filing in mid-2027.
  • Research Nov 10, 2026
    In an active-comparator claims cohort published Nov. 10 in the Annals of Internal Medicine, doxycycline for respiratory tract infection in early pregnancy was associated with higher risk of pregnancy loss than amoxicillin (adjusted relative risk 1.54, 95% CI 1.41 to 1.68, in MarketScan and 1.40, 95% CI 1.28 to 1.53, in Medicaid) and than macrolides (1.39 and 1.36). For acne, the association versus topical clindamycin was significant in MarketScan (1.49, 95% CI 1.26 to 1.76) but not in Medicaid (1.03, 95% CI 0.80 to 1.33). The study is observational.
  • Research Nov 12, 2026
    In a national prescription-data cohort published Nov. 12 in Clinical Infectious Diseases, women were less likely to abandon long-acting cabotegravir PrEP than daily oral PrEP (11.9% versus 18.1%, adjusted relative risk 0.68, 95% CI 0.62 to 0.74), while men were more likely to (10.2% versus 8.1%, adjusted relative risk 1.25, 95% CI 1.20 to 1.31). The study covered prescriptions from January 2022 to June 2025.

Latest news

Tagged infectious disease, from the daily briefing

  1. IDSA issues 2026 guideline on preventing invasive aspergillosis in adult solid organ transplant recipients
  2. Two new 16-week tuberculosis regimens show promise against standard therapy in a 401-patient phase 2 NEJM trial
  3. Individual patient data meta-analysis of 3,880 patients estimates current mortality after invasive aspergillosis

See all the latest news

Earlier weeks

The weekly podcast

Each Sunday's infectious disease innovation roundup as a short audio briefing, read by AI voices. Play any episode here, or follow the show in any podcast app.

In any podcast app, add the feed: https://feeds.transistor.fm/physician-in-the-loop-infectious-disease